(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with rivastigmine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arán, VJ; Campillo, NE; Fernández-Ruiz, J; García-Arencibia, M; Girón, R; Gómez-Cañas, M; González-Naranjo, P; Martín, MI; Páez, JA; Pérez, C; Pérez-Macias, N; Sánchez-Robles, E | 1 |
| Campillo, NE; de Ceballos, ML; Girón, R; González-Naranjo, P; Martín-Fontelles, MI; Martin-Requero, A; Páez, JA; Pérez, C; Pérez-Macias, N; Roca, C; Sánchez-Robles, E; Vaca, G | 1 |
2 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and rivastigmine
| Article | Year |
|---|---|
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cannabinoid Receptor Agonists; Cholinesterase Inhibitors; Computational Biology; Drug Design; Horses; Humans; Indazoles; Ligands; Molecular Docking Simulation; Molecular Structure; Radioligand Assay; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2014 |
Indazolylketones as new multitarget cannabinoid drugs.
Topics: Aspartic Acid Endopeptidases; Butyrylcholinesterase; Cannabinoids; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Design; Humans; Indazoles; Ketones; Neurons; Receptor, Cannabinoid, CB2 | 2019 |